期刊
BLOOD
卷 122, 期 3, 页码 434-442出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2013-01-478776
关键词
-
类别
资金
- National Institutes of Health, National Heart, Lung, and Blood Institute [N01-HB-47110]
- National Heart, Lung, and Blood Institute [HHSN268200625226C, RO1 HL079915, RC2-HL101212]
- Doris Duke Charitable Foundation [2009089]
- Canada Research Chair Program
- Canadian Institute of Health Research [123382]
- Fonds de Recherche Sante Quebec
Patients with sickle cell disease (SCD) present with a wide range of clinical complications. Understanding this clinical heterogeneity offers the prospects to tailor the right treatments to the right patients and also guide the development of novel therapies. Several environmental (eg, nutrition) and nonenvironmental (eg, fetal hemoglobin levels, alpha-thalassemia status) factors are known to modify SCD severity. To find new genetic modifiers of SCD severity, we performed a gene-centric association study in 1514 African American participants from the Cooperative Study of Sickle Cell Disease (CSSCD) for acute chest syndrome (ACS) and painful crisis. From the initial results, we selected 36 single nucleotide polymorphism (SNPs) and genotyped them for replication in 387 independent patients from the CSSCD, 318 SCD patients recruited at Georgia Health Sciences University, and 449 patients from the Duke SCD cohort. In the combined analysis, an association between ACS and rs6141803 reached array-wide significance (P = 4.1 x 10(-7)). This SNP is located 8.2 kilobases upstream of COMMD7, a gene highly expressed in the lung that interacts with nuclear factor-kappa B signaling. Our results provide new leads to gaining a better understanding of clinical variability in SCD, a simple monogenic disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据